MedTrace Logo

State of the Art Photon Therapy Versus Particle Therapy for Recurrent Head & Neck Tumors; a Planning Study

NCT02242916 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 25

Last updated 2016-01-22

No results posted yet for this study

Summary

Given that the cost of proton therapy is considerably higher than that of conventional radiotherapy with photons, it is necessary to establish whether these higher costs are worthwhile in light of the expected advantages2,3,4. Thus, clear evidence of the situations in which proton therapy outperforms conventional photon treatment is needed. The investigators therefore aim to demonstrate through an in silico trial that proton therapy decrease the amount of irradiated normal tissue and, consequently, the risk of side effects in the surrounding normal tissue as well as the risk of secondary tumors. The same overall treatment time and an equal number of fractions will be used for both treatment modalities wherever possible. The most optimal technique for each individual patient, based on objective criteria related to limiting dose to normal tissue, will be prescribed by the institution concerned for each treatment option.

Conditions

  • Carcinoma, Squamous Cell of Head and Neck

Interventions

RADIATION

Photon therapy versus proton therapy

RADIATION

Photon therapy versus C-ion therapy

Sponsors & Collaborators

  • University of Pennsylvania

    collaborator OTHER

  • Philipps University Marburg

    collaborator OTHER

  • University Medical Center Nijmegen

    collaborator OTHER

  • Maastricht Radiation Oncology

    lead OTHER

Principal Investigators

  • Danielle Eekers, Dr. · Maastro Clinic, Dr Tanslaan 12, Maastricht, The Netherlands

  • Philippe lambin, prof, Dr · Maastro Clinic, Dr Tanslaan 12, Maastricht, The Netherlands

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02242916 on ClinicalTrials.gov